Explore our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts.

Sign in Join

August 25 – 31, 2025

A Note from the Editor

Gosh, what a busy week! Monday saw two breaking news stories: AbbVie acquires Gilgamesh Pharmaceuticals’ lead psychedelic candidate in a transaction valued at up to $1.2 billion, and Norwegian regulators approved the use of public funds to cover generic ketamine for treatment-resistant depression. While the first of those two stories signals a growing appetite from ‘big pharma’ to dabble with true psychedelics, the latter story has upset some pharmaceutical firms, especially Johnson & Johnson (more on that here).

Later in the week, we learned that Lykos Therapeutics is renaming itself Resilient Pharmaceuticals, presumably in a nod to the fact that, despite decades of work and last summer’s FDA rejection, the MDMA drug developer keeps pushing on.

On Thursday and Friday, I took part in the Hopkins-Oxford Psychedelics Ethics (HOPE) workshop at The Oxford Union, which was a fantastic, intimate gathering of scholars and scientists (and, well, me!). I look forward to keeping tabs on HOPE’s future outputs.

Anyhow, without further ado: Here’s your Psychedelic News Feed, a one-stop digest for the latest coverage of psychedelics business, policy, research and beyond.

Josh Hardman
Founder & Editor

Psychedelic Bulletin #207

Psychedelic Alpha ↗

  • Lykos Therapeutics Rebrands to Resilient Pharmaceuticals
  • Pharma Pushes Back on Norway’s Off-Label Ketamine Decision
  • AbbVie–Gilgamesh Deal Viewed as Validation for Short-Acting Psychedelics
  • Psilocybin Rescheduling Petition Heads to HHS
  • Sensorium Scores $25M Series A Extension to Take Kanna-Based Candidate Into Clinic
  • Researchers Call Lykos’ MDMA Pricing Modelling “Problematic”
  • Alabama Board of Medicine Issues Guidelines for Off-Label Ketamine in TRD
  • FDA Approves PharmaTher’s Ketamine After Two CRLs
  • Incannex Reports Positive Phase 2 Results for Psilocybin-Assisted Psychotherapy in GAD
  • and more…

August 18 – 24, 2025

August 11 – 17, 2025

August 4 – 10, 2025

Psychedelic Bulletin #206

Psychedelic Alpha ↗

  • Q2’25 Psychedelic Lobbying Update
  • Tabernanthalog Spurs Neuroplasticity via Alternative Pathway, Davis and Delix Researchers Find
  • UK Moves Toward Easing Schedule I Research Restrictions But Keeps Industry at Arm’s Length
  • “Shell Games” and Whistleblowers: MassGOP Goes on Offensive Against Psychedelics Campaigners
  • Aussie University Seeks Public Comments on MDMA Clinical Practice Guideline
  • and more…

July 28 – August 3, 2025

Psychedelic Bulletin #205

Psychedelic Alpha ↗

  • AbbVie Eyes Billion-Dollar Gilgamesh Acquisition
  • What Is Kyrsten Sinema Selling?
  • Compass Pathways ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program
  • Psychedelics Industry’s Input on EMA’s Draft Depression Guideline
  • National Survey Reveals Psychedelics Use Again Rises in US
  • FDA Moves to Ban Kratom Compound 7-OH
  • Compass Talks Accelerated Approval on Q2’25 Earnings Call
  • atai All-In on Psychedelics Following RL-007 Flop
  • UK Government Publishes Life Sciences Plan
  • NMDA or Opioid? Ketamine’s True Target Under Scrutiny
  • Budget, Dosing, and Paperwork Raised at OPS Listening Sessions
  • and more…

Pα+

An insider’s guide to the business,
policy and science of psychedelics.

Basic

Free subscribers receive a weekly round-up
of news on psychedelics, as well as the occasional article.

Receive regular bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments.

Monthly $20 Annually $200

Teams

Teams, groups and corporate pricing plans are available, please get in touch via email
to learn more.

Benefits

Front-row access to the psychedelics space: breaking bulletins, in-depth articles, insider interviews and sharp analysis of the moments that matter—from major trial results and funding rounds to policy shifts shaping the future. Plus, full access to our complete
archive and Library.

Learn More
  Free
Weekly Psychedelic News Feed
Occasional Articles & Free Resources
Psychedelic Bulletins (In-Depth Briefings, Multiple per Month)
Quick-Take Analysis of Major Developments
In-Depth Articles & Deep Dives
Exclusive Interviews with Insiders & KOLs
Quarterly Video Briefings
Exclusive Tools & Data Resources
Library of Primers & Explainers

Subscribe Now

Monthly $20 Annually $200

Join Today

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.

Monthly $20 Annually $200

Subscribe to our
free newsletter


By signing up, you agree to our privacy policy. You can unsubscribe at any time.

Learn More About

Group, team &
corporate plans


Aside from group pricing, we also offer bespoke reports and regular briefings. Get in touch to discuss.